We are live on ! Find out more
VIR icon

Vir Biotechnology
VIR

209 hedge funds and large institutions have $901M invested in Vir Biotechnology in 2024 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 71 increasing their positions, 68 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 27

13% more call options, than puts

Call options by funds: $3.04M | Put options by funds: $2.7M

1% more funds holding

Funds holding: 206 → 209 (+3)

4% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 68

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less capital invested

Capital invested by funds: $909M → $901M (-$7.72M)

1.31% less ownership

Funds ownership: 67.13% → 65.83% (-1.3%)

Holders
209
Holders Change
+3
Holders Change %
+1.46%
% of All Funds
3.01%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
31
Increased
71
Reduced
68
Closed
27
Calls
$3.04M
Puts
$2.7M
Net Calls
+$342K
Net Calls Change
-$1M

Top Buyers

1
Bank of America
Bank of America
North Carolina
+$10M
2
Citigroup
Citigroup
New York
+$9.36M
3
Barclays
Barclays
United Kingdom
+$5.8M
4
O
OrbiMed
New York
+$5.49M
5
Citadel Advisors
Citadel Advisors
Florida
+$3.77M

Top Sellers

1
AllianceBernstein
AllianceBernstein
Tennessee
-$27.2M
2
Morgan Stanley
Morgan Stanley
New York
-$19.5M
3
Prudential Financial
Prudential Financial
New Jersey
-$3.29M
4
TC
TwinBeech Capital
New York
-$3.22M
5
BlackRock
BlackRock
New York
-$3.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
AWM
201
Avior Wealth Management
Nebraska
$162 +$163 +16 New
FCA
202
FinTrust Capital Advisors
South Carolina
$142 – – –
SIC
203
SJS Investment Consulting
Ohio
$122 – – –
RIL
204
Rothschild Investment LLC
Illinois
$101 +$102 +10 New
AWM
205
Abound Wealth Management
Tennessee
$92 – – –
DPW
206
DiNuzzo Private Wealth
Pennsylvania
$51 -$20 -2 -29%
Northwestern Mutual Wealth Management
207
Northwestern Mutual Wealth Management
Wisconsin
$51 +$51 +5 New
FGAM
208
Financial Gravity Asset Management
Texas
$3 – – –
TC
209
TwinBeech Capital
New York
– -$3.22M -319,872 Closed
Squarepoint
210
Squarepoint
New York
– -$2.23M -221,855 Closed
SGA
211
Sector Gamma AS
Norway
– -$1.49M -148,538 Closed
SG Americas Securities
212
SG Americas Securities
New York
– -$970K -96,431 Closed
PAM
213
Panagora Asset Management
Massachusetts
– -$951K -94,516 Closed
HF
214
HRT Financial
New York
– -$614K -61,095 Closed
LCM
215
Landscape Capital Management
New Jersey
– -$489K -48,606 Closed
Schroder Investment Management Group
216
Schroder Investment Management Group
United Kingdom
– -$473K -47,000 Closed
Bank Julius Baer & Co
217
Bank Julius Baer & Co
Switzerland
– -$336K -33,389 Closed
AG
218
Algert Global
California
– -$322K -31,960 Closed
SO
219
STRS Ohio
Ohio
– -$266K -26,500 Closed
GCM
220
Graham Capital Management
Connecticut
– -$244K -24,254 Closed
AC
221
Aristides Capital
Kentucky
– -$239K -23,743 Closed
DT
222
Diversified Trust
Tennessee
– -$214K -21,268 Closed
PMEF
223
Point72 Middle East FZE
United Arab Emirates
– -$128K -12,698 Closed
Janney Montgomery Scott
224
Janney Montgomery Scott
Pennsylvania
– -$123K -12,180 Closed
Baird Financial Group
225
Baird Financial Group
Wisconsin
– -$103K -10,204 Closed
6 7 8
9
10

VIR Hedge Fund Activity: Q1 2024 in Review

209 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q1 2024, worth a combined $901M — down 0.85% from $909M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new VIR positions and 27 closed out — a net gain of 4 holders — while 71 added to existing stakes and 68 trimmed.

The largest buyer was Bank of America, adding an estimated $10M. The largest seller was AllianceBernstein, cutting an estimated $27.2M.

  • 209 institutional investors held Vir Biotechnology (VIR) as of Q1 2024, up from 206 in Q4 2023.
  • Funds reported $901M of Vir Biotechnology stock for Q1 2024, down 0.85% quarter-over-quarter.
  • 31 funds opened new Vir Biotechnology positions in Q1 2024 and 27 closed out, a net change of +4 holders.
  • The largest Vir Biotechnology buyer in Q1 2024 was Bank of America, an estimated $10M added.
  • The largest Vir Biotechnology seller in Q1 2024 was AllianceBernstein, an estimated $27.2M sold.

Based on aggregated 13F filings for Q1 2024.